Search research articles
Contact Us
Filters
Showing results (221-230 of 493) with videos related to
Page
of 50
Sort By:
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
January 18, 2014
Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution
Janice P Dutcher, Donna Neuberg, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer
|
September 25, 2019
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, et al.
British Journal of Psychology (London, England : 1953)
|
August 11, 2018
Does your mindfulness benefit others? A systematic review and meta-analysis of the link between mindfulness and prosocial behaviour
James N Donald, Baljinder K Sahdra, Brooke Van Zanden, et al.
Medical Oncology (Northwood, London, England)
|
November 20, 1998
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon
R K Alpaugh, M von Mehren, I Palazzo, et al.
Cancers
|
December 10, 2021
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
Dongyu Zhang, Neil J Shah, Michael Cook, et al.
Cancer
|
September 4, 2009
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma
John Glaspy, Michael B Atkins, Jon M Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
Diana C Gallagher, Rupal S Bhatt, Samir M Parikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group
Michael B Atkins, Jessie Hsu, Sandra Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma
Michael B Atkins, Jared A Gollob, Jeffrey A Sosman, et al.
Journal of Clinical Immunology
|
November 1, 1986
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)
M Allegretta, M B Atkins, R A Dempsey, et al.
Page
of 50
Search research articles
Search
Showing results (221-230 of 493) with videos related to
Sort By:
Page
of 50
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
January 18, 2014
Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution
Janice P Dutcher, Donna Neuberg, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer
|
September 25, 2019
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, et al.
British Journal of Psychology (London, England : 1953)
|
August 11, 2018
Does your mindfulness benefit others? A systematic review and meta-analysis of the link between mindfulness and prosocial behaviour
James N Donald, Baljinder K Sahdra, Brooke Van Zanden, et al.
Medical Oncology (Northwood, London, England)
|
November 20, 1998
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon
R K Alpaugh, M von Mehren, I Palazzo, et al.
Cancers
|
December 10, 2021
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
Dongyu Zhang, Neil J Shah, Michael Cook, et al.
Cancer
|
September 4, 2009
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma
John Glaspy, Michael B Atkins, Jon M Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
Diana C Gallagher, Rupal S Bhatt, Samir M Parikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group
Michael B Atkins, Jessie Hsu, Sandra Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma
Michael B Atkins, Jared A Gollob, Jeffrey A Sosman, et al.
Journal of Clinical Immunology
|
November 1, 1986
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)
M Allegretta, M B Atkins, R A Dempsey, et al.
Page
of 50